Primary ovarian carcinoid tumors may express CDX-2: A potential pitfall in distinction from metastatic intestinal carcinoid tumors involving the ovary

International Journal of Gynecological Pathology

Volumn 28, Issue 1, 2009, Pages 41-48

  Rabban, Joseph T ^a   Lerwill, Melinda F ^b   McCluggage, W Glenn ^c   Grenert, James P ^a   Zaloudek, Charles J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

Carcinoid tumor; CDX 2; Ovary

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 20; CYTOKERATIN 7; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR CDX2; CDX 2 3 PROTEIN; CDX-2-3 PROTEIN; HOMEODOMAIN PROTEIN; TRANSACTIVATOR PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARCINOID; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE TUMOR; MAJOR CLINICAL STUDY; METASTASIS; OVARY TUMOR; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; TERATOMA; TISSUE DIFFERENTIATION; METABOLISM; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; CARCINOID TUMOR; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL NEOPLASMS; MIDDLE AGED; OVARIAN NEOPLASMS; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 61449317997     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/PGP.0b013e31817a8f51     Document Type: Article

References (23)

1. Davis KP, Hartmann LK, Keeney GL, et al. Primary ovarian carcinoid tumors. Gynecol Oncol 1996;61:259-265
2. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934-959 (Pubitemid 36173145)
3. Robboy SJ, Scully RE, Norris HJ. Carcinoid metastatic to the ovary. A clinicopathologic analysis of 35 cases. Cancer 1974; 33:798-811.
4. Strosberg J, Nasir A, Cragun J, et al. Metastatic carcinoid tumor to the ovary: a clinicopathologic analysis of seventeen cases. Gynecol Oncol 2007 . (Pubitemid 46898572)
5. Baker PM, Oliva E, Young RH, et al. Ovarian mucinous carcinoids including some with a carcinomatous component: a report of 17 cases. Am J Surg Pathol 2001;25:557-568 (Pubitemid 32423352)
6. Robboy SJ, Norris HJ, Scully RE. Insular carcinoid primary in the ovary. A clinicopathologic analysis of 48 cases. Cancer 1975;36:404-418
7. Robboy SJ, Scully RE, Norris HJ. Primary trabecular carcinoid of the ovary. Obstet Gynecol 1977;49:202-207
8. Talerman A, Evans MI. Primary trabecular carcinoid tumor of the ovary. Cancer 1982;50:1403-1407 (Pubitemid 12031965)
9. Drummond F, Putt W, Fox M, et al. Cloning and chromosome assignment of the human CDX2 gene. Ann Hum Genet 1997; 61:393-400. (Pubitemid 28040820)
10. Freund JN, Domon-Dell C, Kedinger M, et al. The Cdx-1 and Cdx-2 homeobox genes in the intestine. Biochem Cell Biol 1998; 76:957-969 (Pubitemid 29450564)
11. Suh E, Traber PG. An intestine-specific homeobox gene regulates proliferation and differentiation.Mol Cell Biol 1996;16:619-625
12. La RS, Rigoli E, Uccella S, et al. CDX2 as a marker of intestinal EC-cells and related well-differentiated endocrine tumors. Virchows Arch 2004;445:248-254 (Pubitemid 39286892)
13. Erickson LA, Papouchado B, Dimashkieh H, et al. Cdx2 as a marker for neuroendocrine tumors of unknown primary sites. Endocr Pathol 2004;15:247-252 (Pubitemid 40169418)
14. Jaffee IM, Rahmani M, Singhal MG, et al. Expression of the intestinal transcription factor CDX2 in carcinoid tumors is a marker of midgut origin. Arch Pathol Lab Med 2006;130: 1522-1526 (Pubitemid 44520720)
15. Moskaluk CA, Zhang H, Powell SM, et al. Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays. Mod Pathol 2003;16:913-919 (Pubitemid 37152021)
16. Oliveira AM, Tazelaar HD, Myers JL, et al. Thyroid transcription factor-1 distinguishes metastatic pulmonary from well-differentiated neuroendocrine tumors of other sites. Am J Surg Pathol 2001;25:815-819
17. Saqi A, Alexis D, Remotti F, et al. Usefulness of CDX2 and TTF-1 in differentiating gastrointestinal from pulmonary carcinoids. Am J Clin Pathol 2005;123:394-404. (Pubitemid 40315081)
18. Werling RW, Yaziji H, Bacchi CE, et al. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 2003;27:303-310 (Pubitemid 36245795)
19. Cai YC, Banner B, Glickman J, et al. Cytokeratin 7 and 20 and thyroid transcription factor 1 can help distinguish pulmonary from gastrointestinal carcinoid and pancreatic endocrine tumors. Hum Pathol 2001;32:1087-1093 (Pubitemid 33015669)
20. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol 2000;13:962-972 (Pubitemid 30736647)
21. Robboy SJ, Scully RE. Strumal carcinoid of the ovary: an analysis of 50 cases of a distinctive tumor composed of thyroid tissue and carcinoid. Cancer 1980;46:2019-2034
22. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997;79:813-829 (Pubitemid 27076348)
23. McCluggage WG, Sargent A, Bailey A, et al. Large cell neuroendocrine carcinoma of the uterine cervix exhibiting TTF1 immunoreactivity. Histopathology 2007;51:405-407 (Pubitemid 47301611)